Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
12Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
IGC Pharma, Inc. (IGC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
24Total relationships
5Distinct source URLs
9High confidence
0.761Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
IGC Pharma, Inc. Suppliers
Ticker
Name
Confidence
Evidence
O-BANK-CO-LTD
O-BANK-CO-LTD
92%
IGC Pharma, Inc. entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the "Loan Agreement") with O-Bank…
ODK-CAPITAL-LLC
ODK-CAPITAL-LLC
92%
On February 2, 2026, the Company, through its subsidiary HH Processors, LLC, entered into a loan agreement with ODK Capital LLC
VANQUISH-FUNDING-GROUP-INC
VANQUISH-FUNDING-GROUP-INC
92%
On March 5, 2026, the Company entered into a Securities Purchase Agreement with Vanquish Funding Group Inc.
ONE-DECK-CAPITAL-INC
ONE-DECK-CAPITAL-INC
90%
The Company entered into a loan agreement with One Deck Capital, Inc. ("One Deck"), pursuant to which the Company received approximately $219,000 in financing (the "One Deck Loan")
VFG
VFG
90%
VFG is prohibited from converting any amount of the Note that would result in VFG and its affiliates beneficially owning more than 4.99% of the outstanding shares of Common Stock
Reciprocal relationship from AXSM graph: Reciprocal relationship from IGC graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from IGC graph: ing growth of the Life Sciences segme…
ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage our …
ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage our …
Reciprocal relationship from ORANY graph: Reciprocal relationship from IGC graph: ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative produ…
IGC Pharma, Inc. Customers
Ticker
Name
Confidence
Evidence
FMW-MEDIA-WORKS-LLC
FMW-MEDIA-WORKS-LLC
90%
The Company issued a press release announcing a strategic national media partnership with FMW Media Works LLC
Reciprocal relationship from AXSM graph: Reciprocal relationship from IGC graph: ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative produc…
ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage our …
ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage our …
Reciprocal relationship from ORANY graph: Reciprocal relationship from IGC graph: ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative produ…
DOMINION-MEDICAL-ASSOCIATES-INC
DOMINION-MEDICAL-ASSOCIATES-INC
62%
ng tox studies to enable disease modifying trials with IGC-AD1. ● Applying for non-dilutive grants. ● Advancing TGR-63 as a potential therapeutic for AD. ● Strengthening clinical credibility and visi…
HAMSA-BIOPHARMA-INDIA-PVT-LTD
HAMSA-BIOPHARMA-INDIA-PVT-LTD
62%
atient distress, caregiver burden, and healthcare utilization. In addition to symptom management, preclinical studies of IGC-AD1 suggest activity against biological pathways associated with Alzheimer…
HH-PROCESSORS-LLC
HH-PROCESSORS-LLC
62%
orting data, and the expense associated with filing various patent applications in different countries, along with granted patents. It also includes acquisition costs related to domains and licenses.…
HOLI-HEMP-LLC
HOLI-HEMP-LLC
62%
orting data, and the expense associated with filing various patent applications in different countries, along with granted patents. It also includes acquisition costs related to domains and licenses.…
INTEGRATIVE-CLINICAL-TRIALS-LLC
INTEGRATIVE-CLINICAL-TRIALS-LLC
62%
ng tox studies to enable disease modifying trials with IGC-AD1. ● Applying for non-dilutive grants. ● Advancing TGR-63 as a potential therapeutic for AD. ● Strengthening clinical credibility and visi…
O-BANK-CO-LTD
O-BANK-CO-LTD
62%
atient distress, caregiver burden, and healthcare utilization. In addition to symptom management, preclinical studies of IGC-AD1 suggest activity against biological pathways associated with Alzheimer…
WELLNESS-ESSENTIALS-NORTHWEST-LLC
WELLNESS-ESSENTIALS-NORTHWEST-LLC
62%
orting data, and the expense associated with filing various patent applications in different countries, along with granted patents. It also includes acquisition costs related to domains and licenses.…
IGC Pharma, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IGC-DEBT-10198
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2019-03-31.
IGC-DEBT
Debt stack $136,000
90%
Market cache reports total debt of $136,000.
IGC-DEBT-10197
Warrants outstanding: 1167217
90%
xbrl warrant detail from xbrl 2021-03-31.
IGC Pharma, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for IGC Pharma, Inc..
IGC Pharma, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for IGC Pharma, Inc..
